A carregar...
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2018-09-01
|
| Colecção: | Therapeutic Advances in Respiratory Disease |
| Acesso em linha: | https://doi.org/10.1177/1753466618801167 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|